Dosage Form
Oral Solid Dose CDMOs
Compare CDMOs manufacturing oral solid dosage forms -- tablets, capsules, and modified-release products. Filter by batch size, coating technology, and regulatory approvals.
276 companies listed
About Oral Solid Dose Manufacturing
Oral solid dose (OSD) is the most common pharmaceutical dosage form, accounting for approximately 60% of all drug products. Manufacturing involves blending, granulation (wet or dry), compression or encapsulation, film coating, and packaging. CDMOs range from small clinical-batch operations to high-throughput commercial manufacturers producing millions of units daily.
Modified-release technologies differentiate advanced OSD CDMOs. Extended-release, delayed-release, and pulsatile-release formulations improve patient compliance and can extend product lifecycle. Technologies include matrix tablets, osmotic systems, multiparticulate systems (coated pellets in capsules), and multi-layer tablets for combination products.
Scale is a key selection criterion. Clinical-phase OSD often runs in batches of 5,000-50,000 units. Commercial scale may mean 500,000+ units per batch. Equipment compatibility (granulators, presses, coaters) must match your projected volumes. Ask about batch success rates and changeover times between products.
Companies (276)
7bridges (the7bridges.com)
United Kingdom
7bridges (the7bridges.com) is a pharmaceutical CDMO offering comprehensive services.
Small Molecule APISmall Molecule Drug ProductOral Solid Dose
Avara Pharmaceutical Services
United States
Avara Pharmaceutical Services is a pharmaceutical CDMO offering comprehensive services.
Small Molecule APISmall Molecule Drug ProductOral Solid Dose
Frequently Asked Questions
What types of oral solid dose forms can CDMOs produce?+
Common forms include: immediate-release tablets, film-coated tablets, enteric-coated tablets, extended-release tablets, orally disintegrating tablets (ODTs), hard gelatin capsules, HPMC capsules, softgel capsules, modified-release pellets in capsules, and powder-filled capsules. Specialty forms include multi-layer tablets, osmotic tablets (OROS), and abuse-deterrent formulations.
What is the typical timeline for developing an oral solid dose product?+
From API availability to first clinical batch: 3-6 months for standard formulations, 6-12 months for modified-release. Process development through commercial validation: additional 6-12 months. Total from formulation start to commercial readiness: 12-24 months. Bioavailability-enhancement formulations (amorphous dispersions, nanoparticles) add 3-6 months for technology selection and optimization.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
